稳定型冠状动脉疾病血运重建的争议。
Controversies in revascularisation for stable coronary artery disease.
机构信息
National Heart and Lung Institute, London, UK and Hammersmith Hospital, London, UK
National Heart and Lung Institute, London, UK and Hammersmith Hospital, London, UK.
出版信息
Clin Med (Lond). 2021 Mar;21(2):114-118. doi: 10.7861/clinmed.2020-0922.
Abstract
Recent randomised controlled trials, such as ISCHEMIA and ORBITA, have overturned most of what we were taught in medical school about hospital procedures considered necessary for patients with stable coronary artery disease. In this article, we discuss what these trials mean for physicians and patients considering revascularisation procedures with the hope of reducing the risk of death or alleviating angina.
摘要
最近的随机对照试验，如 ISCHEMIA 和 ORBITA，推翻了我们在医学院所学的大多数关于稳定型冠心病患者所需的医院程序的知识。在本文中，我们讨论了这些试验对考虑进行血管重建手术的医生和患者意味着什么，希望能降低死亡风险或减轻心绞痛。
相似文献
1
Controversies in revascularisation for stable coronary artery disease.
Clin Med (Lond). 2021 Mar;21(2):114-118. doi: 10.7861/clinmed.2020-0922.
2
Optimising physiological endpoints of percutaneous coronary intervention.
EuroIntervention. 2021 Apr 2;16(18):e1470-e1483. doi: 10.4244/EIJ-D-20-00988.
3
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22.
4
Impact of a comprehensive cardiac rehabilitation programme versus coronary revascularisation in patients with stable angina pectoris: study protocol for the PRO-FIT randomised controlled trial.
BMC Cardiovasc Disord. 2023 May 5;23(1):238. doi: 10.1186/s12872-023-03266-z.
5
COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease.
Interv Cardiol Clin. 2020 Oct;9(4):469-482. doi: 10.1016/j.iccl.2020.07.003.
6
Outcome of revascularisation in stable coronary artery disease without ischaemia: a Danish registry-based follow-up study.
BMJ Open. 2017 Aug 11;7(8):e016169. doi: 10.1136/bmjopen-2017-016169.
7
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.
Circulation. 2025 Jan 21;151(3):202-214. doi: 10.1161/CIRCULATIONAHA.124.072281. Epub 2024 Oct 27.
8
Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
Lancet. 2024 Apr 20;403(10436):1543-1553. doi: 10.1016/S0140-6736(24)00256-3. Epub 2024 Apr 8.
9
Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results From the ORBITA-2 Trial.
J Am Coll Cardiol. 2025 May 13;85(18):1740-1753. doi: 10.1016/j.jacc.2025.02.034.
10
Percutaneous coronary revascularization versus medical therapy in chronic coronary syndromes: An updated meta-analysis of randomized controlled trials.
Eur J Clin Invest. 2024 Dec;54(12):e14303. doi: 10.1111/eci.14303. Epub 2024 Aug 21.
引用本文的文献
1
Association between NT-proBNP level and the number of stents with major advanced cardiovascular events (MACE) in patients with multivessel coronary artery disease treated with percutaneous coronary intervention: A prospective cohort study.
Narra J. 2024 Apr;4(1):e710. doi: 10.52225/narra.v4i1.710. Epub 2024 Apr 16.
2
Remote digital smart device follow-up in prospective clinical trials: early insights from ORBITA-2, ORBITA-COSMIC, and ORBITA-STAR.
Eur Heart J Suppl. 2022 Nov 11;24(Suppl H):H32-H42. doi: 10.1093/eurheartjsupp/suac058. eCollection 2022 Nov.
3
Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies.
Front Cardiovasc Med. 2022 Jan 10;8:726289. doi: 10.3389/fcvm.2021.726289. eCollection 2021.
本文引用的文献
1
Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation.
Lancet. 2020 Oct 31;396(10260):1399-1412. doi: 10.1016/S0140-6736(20)32114-0. Epub 2020 Oct 8.
2
Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials.
Circulation. 2020 Sep;142(9):841-857. doi: 10.1161/CIRCULATIONAHA.120.048194. Epub 2020 Jun 26.
3
Initial Invasive or Conservative Strategy for Stable Coronary Disease.
N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30.
4
Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials.
Eur Heart J. 2020 Sep 7;41(34):3228-3235. doi: 10.1093/eurheartj/ehaa135.
5
Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials.
Circ Cardiovasc Qual Outcomes. 2020 Feb;13(2):e006363. doi: 10.1161/CIRCOUTCOMES.119.006363. Epub 2020 Feb 17.
6
Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Stress Echocardiography-Stratified Analysis of ORBITA.
Circulation. 2019 Dec 10;140(24):1971-1980. doi: 10.1161/CIRCULATIONAHA.119.042918. Epub 2019 Nov 11.
7
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.
N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28.
8
Mortality From Ischemic Heart Disease.
Circ Cardiovasc Qual Outcomes. 2019 Jun;12(6):e005375. doi: 10.1161/CIRCOUTCOMES.118.005375. Epub 2019 Jun 4.
9
'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.
Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855.
10
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
Circulation. 2018 Oct 23;138(17):1780-1792. doi: 10.1161/CIRCULATIONAHA.118.033801.
Zotero 插件